Drug Addiction (Cocaine)

Clearance Received for Cocaine Vaccine IND

Published in Vaccine Weekly, December 15th, 1997

ImmuLogic Pharmaceutical Corp., Waltham, Massachusetts, announced the U.S. Food and Drug Administration (FDA) clearance of an IND application for a cocaine vaccine therapeutic product.

"The IND was filed on October 29, [1997], in preparation for a planned Phase I clinical trial for the first quarter 1998," said Joseph Marr, MD, ImmuLogic Pharmaceutical Corp. "There are currently no medications approved specifically for treating cocaine addiction. The vaccine technology is a novel approach to address the unmet need in substance abuse treatment."

ImmuLogic previously reported the award of a $2.2 million grant from the National Institute on Drug Abuse...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1997-12-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry